White House advisor Peter Navarro hinted that President Donald Trump might impose tariffs on pharmaceutical products under Section 232 of U.S. trade law. This announcement triggered a decline in the share prices of Pfizer and UnitedHealth, whereas Amgen, Johnson & Johnson, and AstraZeneca ADR witnessed modest gains.
